Recommended Articles
View All
View | Democratising digital markets, the ONDC way
Feb 8, 2023 IST6 Min(s) Read
Worldview: Biden at the State of Union | 'Let’s finish the job'
Feb 8, 2023 IST6 Min(s) Read
Considering buying an SUV? Factor in the waiting period
Feb 8, 2023 IST3 Min(s) Read
Delhi is one of the most populated cities prone to earthquakes in India — can it handle what Turkey couldn't
Feb 7, 2023 IST6 Min(s) Read
Strides Pharma Global Pte. Ltd. (SPG), a step-down subsidiary of Bengaluru-based Strides Pharma Science Ltd., has received Rs 525 crore (A$ 394 million) as deferred consideration for the sale of the company’s operations in Australia in 2019.
The company will utilise the proceeds for deleveraging the balance sheet, the pharma major said in a stock exchange filing on Thursday.
Strides exited its investments in Australia for A$394 million in 2019. It received A$300 million immediately on the transaction's closing, and the same was used towards deleveraging of the balance sheet. The remaining A$94 million was a deferred consideration backed by a secured interest-bearing instrument.
Strides Pharma continues to be a preferred supplier to Arrotex, which is the largest generic company in Australia.
The Singapore-based Strides Pharma Global Pte. Ltd. is also the international headquarters for Strides Pharma Science Ltd, which is a B2C focused global pharmaceutical company that mainly operates in the regulated markets of the United States, Australia, Europe and Canada.
